Enfortumab vedotin plus pembrolizumab (EV+P) vs chemotherapy for previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): 3.5-year follow-up and response analyses from the phase 3 EV-302 study.
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Thomas Powles, Michiel S. Van Der Heijden, Jens Bedke, Begoña P. Valderrama, Eiji Kikuchi, Matthew D. Galsky, Yohann Loriot, Gopa Iyer, Evan Y. Yu, Jeannie Hoffman-Censits, Nataliya Mar, Christof Vulsteke, Srikala S. Sridhar, Jose Pablo Maroto-Rey, Se Hoon Park, Blanca Homet Moreno, Jasmine Lichfield, Xuesong Yu, Heidi Wirtz, Shilpa Gupta
Institutions: Queen Mary University of London, The Netherlands Cancer Institute, Klinikum Stuttgart, Hospital Universitario Virgen del Rocío, St. Marianna University School of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, Université Paris-Saclay, Institut Gustave Roussy, Memorial Sloan Kettering Cancer Center, University of Washington, Fred Hutch Cancer Center, Johns Hopkins University, Johns Hopkins Medicine, Johns Hopkins Hospital, Sidney Kimmel Comprehensive Cancer Center, University of California, Irvine, University of Antwerp, AZ Maria Middelares, University of Toronto, Princess Margaret Cancer Centre, Hospital de Sant Pau, Samsung Medical Center, Sungkyunkwan University, Merck & Co., Inc., Rahway, NJ, USA (United States), Astellas Pharma (United Kingdom), Pfizer (United States), Cleveland Clinic
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7162532662